A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Clinical trial NCT01449461 · COMPLETED

Trial details

NCT number: NCT01449461
Sponsor: Ariad Pharmaceuticals
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large-Cell, Anaplastic Carcinoma, Non-Small-Cell Lung

Start date: 2011-09-20
Primary completion: 2015-11-16
Enrollment: 137

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.